Latest news with #UCBBiopharma
Yahoo
19-05-2025
- Business
- Yahoo
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the appointment of Steven Johnson as Chief Development Officer. Steven will join the executive team to lead regulatory and development strategies at Zealand Pharma. His appointment, alongside Chief Medical Officer, David Kendall and recently appointed Chief Scientific Officer, Utpal Singh further strengthens the company's strategy to lead the field in innovation in the management of obesity and other related conditions. Steven brings nearly 30 years of experience driving drug development and regulatory strategy across the pharmaceutical industry. He joins Zealand Pharma from UCB Biopharma, where he most recently served as Senior Vice President and Head of Regulatory Stakeholders, responsible for leading late phase clinical development, global regulatory affairs, biometrics and operational excellence. During Steven's tenure at UCB, his teams secured global approvals for key therapies across multiple therapeutic areas. Previously he had senior leadership roles at Medpace, Inc. and at Novo Nordisk. Steven began his career at the U.S. Food and Drug Administration, where he served as a Master Reviewer in the Division of Metabolic and Endocrine Drug Products. 'Steven brings a unique 360-degree perspective on global drug development gained from a career at major pharma companies, CROs and the FDA,' said Adam Steensberg, Chief Executive Officer, Zealand Pharma. 'He joins Zealand at a key moment as we embark on the collaboration with Roche to co-develop and co-commercialize petrelintide as a foundational therapy for people with overweight and obesity. Together, Utpal, Steven and David form a robust, seamless leadership team across research, development and medical affairs as we strive to become a leader in the management of obesity and related complications.' Steven Johnson added, 'Zealand Pharma is committed to delivering transformative therapies that are created with the patient's experience in mind to support long-term health outcomes. I'm excited to work alongside this exceptional team aligning human centered innovation with world class science to develop new therapies that could redefine the standard of care for obesity and more.' Steven was a Geriatrics Fellow at Washington State University and holds a PharmD, a BPharm, and a BS in Biology, also from Washington State University. About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a team in the U.S. For more information about Zealand Pharma's business and activities, please visit Forward looking statementsThis press release contains 'forward-looking statements', as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@ Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@ Anna Krassowska, PhD (Investor and Media)Vice President, Investor Relations & Corporate Communicationsakrassowska@ Amber Fennell, Jessica Hodgson, Sean Leous (Media)ICR HealthcareZealandPharma@ (0) 7739 658 783Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
19-05-2025
- Business
- Yahoo
Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer
Press release – No. 9 / 2025 Zealand Pharma continues to strengthen strategic leadership of innovation in obesity and related conditions with appointment of Steven Johnson as Chief Development Officer Steven will lead the regulatory and development strategies that position Zealand Pharma at the forefront of innovation in the management of obesity and other related complications He joins CMO David Kendall and recently appointed CSO Utpal Singh to strengthen Zealand Pharma's R&D leadership and progress its differentiated clinical pipeline of potential best-in-class peptide therapeutics Copenhagen, Denmark, May 19, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today announces the appointment of Steven Johnson as Chief Development Officer. Steven will join the executive team to lead regulatory and development strategies at Zealand Pharma. His appointment, alongside Chief Medical Officer, David Kendall and recently appointed Chief Scientific Officer, Utpal Singh further strengthens the company's strategy to lead the field in innovation in the management of obesity and other related conditions. Steven brings nearly 30 years of experience driving drug development and regulatory strategy across the pharmaceutical industry. He joins Zealand Pharma from UCB Biopharma, where he most recently served as Senior Vice President and Head of Regulatory Stakeholders, responsible for leading late phase clinical development, global regulatory affairs, biometrics and operational excellence. During Steven's tenure at UCB, his teams secured global approvals for key therapies across multiple therapeutic areas. Previously he had senior leadership roles at Medpace, Inc. and at Novo Nordisk. Steven began his career at the U.S. Food and Drug Administration, where he served as a Master Reviewer in the Division of Metabolic and Endocrine Drug Products. 'Steven brings a unique 360-degree perspective on global drug development gained from a career at major pharma companies, CROs and the FDA,' said Adam Steensberg, Chief Executive Officer, Zealand Pharma. 'He joins Zealand at a key moment as we embark on the collaboration with Roche to co-develop and co-commercialize petrelintide as a foundational therapy for people with overweight and obesity. Together, Utpal, Steven and David form a robust, seamless leadership team across research, development and medical affairs as we strive to become a leader in the management of obesity and related complications.' Steven Johnson added, 'Zealand Pharma is committed to delivering transformative therapies that are created with the patient's experience in mind to support long-term health outcomes. I'm excited to work alongside this exceptional team aligning human centered innovation with world class science to develop new therapies that could redefine the standard of care for obesity and more.' Steven was a Geriatrics Fellow at Washington State University and holds a PharmD, a BPharm, and a BS in Biology, also from Washington State University. About Zealand Pharma A/SZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on the discovery and development of peptide-based medicines. More than 10 drug candidates invented by Zealand Pharma have advanced into clinical development, of which two have reached the market and three candidates are in late-stage development. The company has development partnerships with a number of pharma companies as well as commercial partnerships for its marketed products. Zealand Pharma was founded in 1998 and is headquartered in Copenhagen, Denmark, with a team in the U.S. For more information about Zealand Pharma's business and activities, please visit Forward looking statementsThis press release contains 'forward-looking statements', as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Pharma's expectations or forecasts of future events regarding the research, development and commercialization of pharmaceutical products, the timing of the company's pre-clinical and clinical trials and the reporting of data therefrom. These forward-looking statements may be identified by words such as 'aim,' 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'forecast,' 'goal,' 'intend,' 'may,' 'plan,' 'possible,' 'potential,' 'will,' 'would' and other words and terms of similar meaning. You should not place undue reliance on these statements, or the scientific data presented. The reader is cautioned not to rely on these forward-looking statements. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions, which may cause actual results to differ materially from expectations set forth herein and may cause any or all of such forward-looking statements to be incorrect, and which include, but are not limited to, unexpected costs or delays in clinical trials and other development activities due to adverse safety events, patient recruitment or otherwise; unexpected concerns that may arise from additional data, analysis or results obtained during clinical trials; our ability to successfully market both new and existing products; changes in reimbursement rules and governmental laws and related interpretation thereof; government-mandated or market-driven price decreases for our products; introduction of competing products; production problems at third party manufacturers; dependency on third parties, for instance contract research or development organizations; unexpected growth in costs and expenses; our ability to affect the strategic reorganization of our businesses in the manner planned; failure to protect and enforce our data, intellectual property and other proprietary rights and uncertainties relating to intellectual property claims and challenges; regulatory authorities may require additional information or further studies, or may reject, fail to approve or may delay approval of our drug candidates or expansion of product labeling; failure to obtain regulatory approvals in other jurisdictions; exposure to product liability and other claims; interest rate and currency exchange rate fluctuations; unexpected contract breaches or terminations; inflationary pressures on the global economy; and political uncertainty. If any or all of such forward-looking statements prove to be incorrect, our actual results could differ materially and adversely from those anticipated or implied by such statements. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. All such forward-looking statements speak only as of the date of this company announcement and are based on information available to Zealand Pharma as of the date of this announcement. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Information concerning pharmaceuticals (including compounds under development) contained within this material is not intended as advertising or medical advice. ContactsAdam Lange (Investors)Vice President, Investor Relationsalange@ Neshat Ahmadi (Investors)Investor Relations Managerneahmadi@ Anna Krassowska, PhD (Investor and Media)Vice President, Investor Relations & Corporate Communicationsakrassowska@ Amber Fennell, Jessica Hodgson, Sean Leous (Media)ICR HealthcareZealandPharma@ (0) 7739 658 783Sign in to access your portfolio
Globe and Mail
14-04-2025
- Health
- Globe and Mail
Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis
The Key Arthralgia Companies in the market include - Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others. DelveInsight's 'Arthralgia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Arthralgia, historical and forecasted epidemiology as well as the Arthralgia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Arthralgia Market Report: The Arthralgia market size is estimated to grow with a significant CAGR during the study period (2019-2032) Arthralgia affected women more than it did men, according to DelveInsight's data. For example, in Japan in 2021, there were about 34,000 cases of Arthralgia in males and about 39,000 in females. Key Arthralgia Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others Key Arthralgia Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab and others The Arthralgia epidemiology based on gender analyzed that the prevalence of moderate cases is the highest, followed by severe and mild cases The Arthralgia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Arthralgia pipeline products will significantly revolutionize the Arthralgia market dynamics. Arthralgia Overview Arthralgia is a medical term used to describe pain or discomfort in one or more joints. Joints are the connections between bones, and arthralgia can affect various parts of the body, such as the knees, elbows, wrists, or shoulders. The pain associated with arthralgia can be caused by inflammation, injury, infection, or other underlying conditions affecting the joints. Arthralgia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Arthralgia Epidemiology Segmentation: The Arthralgia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Download the report to understand which factors are driving Arthralgia epidemiology trends @ Arthralgia Epidemiology Forecast Arthralgia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Arthralgia market or expected to get launched during the study period. The analysis covers Arthralgia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Arthralgia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Arthralgia Therapies and Key Companies Discover more about therapies set to grab major Arthralgia market share @ Arthralgia Treatment Market Arthralgia Market Strengths Increased prevalence, growth in awareness, and lifestyle changes have necessitated changes in the diagnosis and treatment of PsA in the recent decade Various screening tools, including self-administered questionnaires, have been developed to help dermatologists, rheumatologist, and general physicians to identify patients who might suffer from PsA Arthralgia Market Unmet Needs Lack of biomarkers Challenges in current treatment options Challenges in current guidelines Poor disease understanding Challenges in managing comorbidities Scope of the Arthralgia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Arthralgia Companies: Sun Pharma, Bristol-Myers Squibb, UCB Biopharma, Affibody AB, Sun Pharmaceutical Industries, Ventyx Biosciences, Aclaris Therapeutics, AbbVie, Novartis, Janssen Research & Development, LLC, MoonLake Immunotherapeutics AG, and others Key Arthralgia Therapies: ILUMYA, Deucravacitinib, Bimekizumab, Izokibep, SUNPG18_07, VTX958, ATI-450, Risankizumab, Upadacitinib, AIN457, Ustekinumab, Sonelokimab, and others Arthralgia Therapeutic Assessment: Arthralgia current marketed and Arthralgia emerging therapies Arthralgia Market Dynamics: Arthralgia market drivers and Arthralgia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Arthralgia Unmet Needs, KOL's views, Analyst's views, Arthralgia Market Access and Reimbursement Table of Contents 1. Arthralgia Market Report Introduction 2. Executive Summary for Arthralgia 3. SWOT analysis of Arthralgia 4. Arthralgia Patient Share (%) Overview at a Glance 5. Arthralgia Market Overview at a Glance 6. Arthralgia Disease Background and Overview 7. Arthralgia Epidemiology and Patient Population 8. Country-Specific Patient Population of Arthralgia 9. Arthralgia Current Treatment and Medical Practices 10. Arthralgia Unmet Needs 11. Arthralgia Emerging Therapies 12. Arthralgia Market Outlook 13. Country-Wise Arthralgia Market Analysis (2019–2032) 14. Arthralgia Market Access and Reimbursement of Therapies 15. Arthralgia Market Drivers 16. Arthralgia Market Barriers 17. Arthralgia Appendix 18. Arthralgia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
